Bio-Path is a biotechnology company focused on the clinical development of therapeutics by utilizing DNAbilize™, our novel and patented method for producing antisense DNA therapeutics for a broad spectrum of indications, including cancer.

An oncology-focused biotechnology company

Bio-Path Holdings is a biotechnology company developing targeted DNA therapeutics for blood cancers and solid tumors.

The company’s lead candidate is prexigebersen (Liposomal Grb2 Antisense), formerly BP1001, for the treatment of acute myeloid leukemia (AML). Prexigebersen is being assessed in a Phase 2 trial in combination with front-line therapy. To date, prexigebersen has demonstrated an excellent safety profile and encouraging anti-leukemic activity in relapsed and refractory patients.

To learn more about prexigebersen and Bio-Path’s other candidates, please click here.

Bio-Path is a biotechnology company focused on the clinical development of therapeutics by utilizing DNAbilize™, our novel and patented method for producing antisense DNA therapeutics for a broad spectrum of indications, including cancer.